June 2021 - BioMedWire (BMW)

WednesdayJun 30, 2021 2:17 pm

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

XPhyto Therapeutics Corp (OTCQB: XPHYF) announced its GMP mescaline synthesis program is “on schedule” The program, which started in early 2021, is slated for completion in late Q3 2021 The first initial production batches were completed successfully, marking a significant milestone for the program Mescaline will form a critical component in XPhyto’s psychedelic medicine program and work towards providing a foundation for its drug formulation and clinical validation work XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) recently announced that its Good Manufacturing Practices (“GMP”) mescaline synthesis program in North America is “on schedule” for completion in late Q3 2021…

WednesdayJun 30, 2021 1:40 pm

Researchers Find Link Between Cellular Aging, Epigenetic Changes in Cancer Patients

A recent study found that some anti-cancer treatments may speed up cellular aging, where changes in a patient’s DNA may contribute to more fatigue and inflammation. The study’s discoveries were reported in the American Cancer Society’s peer-reviewed journal “CANCER.” When epigenetic changes occur or an individual’s DNA is physically modified, the process also can alter gene activity. It should be noted that these changes do not involve adjusting the underlying DNA sequence. Some people may experience epigenetic age acceleration (“EAA”), which increases their risk of age-related conditions, in comparison with other people of the same chronological age. Recently, researchers looked…

TuesdayJun 29, 2021 2:30 pm

What Is Long COVID and What Do We Know About It?

The majority of individuals who contract the coronavirus suffer from the symptoms of coughing, fever and difficulty breathing before recovering in about two weeks. However, some individuals suffer persistent symptoms, informally referred to as long COVID. Researchers estimate that these individuals make up 10% to 30% of the population. While researchers have been unable to find a definitive cause as to why some people suffer from long-term symptoms, they have proposed a few theories as well as growing information about the disease. So, what can we deduce from long COVID? Working definitions from researchers show that the term “long COVID”…

MondayJun 28, 2021 3:00 pm

Study Finds Mass Shooters May Be Suffering from Untreated Mental Illnesses

A study recently published in the “Journal of Clinical Psychopharmacology” has found that some domestic mass shooters in the United States suffer from psychiatric disorders that they haven’t been treated for or received medication for. The report, written by Ira D. Glick and colleagues, highlighted that while most individuals who are mentally ill aren’t violent and most who are violent aren’t mentally ill, their research would be useful to lawyers, mental health providers and the public, who needed to be aware of the fact that some unmedicated individuals pose a higher risk of violence. For their study, the researchers identified…

FridayJun 25, 2021 2:45 pm

Improper Pain Management After Surgical Operations Linked to Opioid Epidemic

A recent report released by researchers from the University of Dundee has found that prescriptions given to alleviate pain after operations are a primary cause of the opioid crisis in some countries. The study, which was reported in “The Lancet,” was co-authored by Prof. Lesley Colvin from the institution. It compiled evidence describing the role surgeries play in the crisis. The authors of the report deduce that pain management has been a significant contributor to the opioid crisis on account of improper prescriptions. As the population grows older and more surgeries are conducted, chronic post-surgical pain continues to become a…

FridayJun 25, 2021 2:17 pm

RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

Cannabis is a chemically variable plant making its clinical trials problematic, before the creation of dose-measuring devices RYAH Smart inhalers being used in one of the largest clinical studies of its kind focused on chronic pain Restrictive funding and legislative barriers regarding cannabis are rapidly dissipating Regulating dose size in cannabis clinical trials has proven problematic from one test subject to another because cannabis is a chemically variable plant. RYAH Group (CSE: RYAH), a health care analytics and technology company, has created IoT dose-measuring devices backed by powerful data analytics, allowing for more control for variables within a clinical setting. …

FridayJun 25, 2021 12:10 pm

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

Dr. Dave Singh, Vivos Therapeutics Inc. founder and Chief Medical Officer, releases his new book titled Pneumopedics and Craniofacial Epigenetics The book is the product of Dr. Singh’s years of research and is a chronology of Vivo Therapeutics’ strides in innovation The book mainly covers craniofacial growth and developmental Genetics It also highlights the relationship between dentofacial anomalies and developmental deficiencies associated with downstream conditions such as Obstructive Sleep Apnea (“OSA”) Since its inception, Vivos Therapeutics (NASDAQ: VVOS) has been a trailblazer in diagnosing and treating mild-to-moderate Obstructive Sleep Apnea (“OSA”). Its main product — Vivos System — results from…

FridayJun 25, 2021 11:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

In 2021, Tryp Therapeutics plans on expanding its academic collaborations It also plans to initiate Phase 2a clinical studies for its synthetic psilocybin drug product as a way to determine efficacy in patient populations Tryp Therapeutics is constantly working on identifying alternative and better ways to control doses and control the patient experience in their dissociative state, mainly through innovations in drug formulation and delivery A primary objective of the administration of psilocybin is to increase the neuroplasticity of the brain Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently shed light on its operations and the vision that it has both…

ThursdayJun 24, 2021 3:18 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Decision represents opportunity to help millions suffering from social, generalized anxiety disorders Global markets will reach an estimated $4 billion this year, with significant growth projected looking forward WHO estimates that 1 in 13 adults globally suffer from anxiety; treatment options have slow onset, undesirable side effects Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, has identified social anxiety disorder, or SAD, and generalized anxiety disorder, or GAD, as the initial target indications for its proprietary psychedelic molecule CYB004 (https://ibn.fm/BQdjY). Collectively, the two global markets will reach an estimated $4 billion this year, with significant…

ThursdayJun 24, 2021 2:16 pm

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

More than 3,200 pharmaceutical and biotech companies, plus government and academic organizations attended latest BIO Conference Predictive Oncology’s Helomics, TumorGenesis, Soluble Biotech all attended the virtual conference from June 14-18, 2021 Companies leveraged different components of the conference to entertain new partnerships or customers Every industry has a revolving calendar of events, but some are “must attends” due to their global reach and prospective deal flow, like conferences put on by Biotechnology Innovation Organization, or just “BIO” as it’s known. This year, three wholly owned subsidiaries of Predictive Oncology (NASDAQ: POAI) – Helomics, TumorGenesis and Soluble Biotech – attended BIO…

News and publishing service for medical and biotechnology related companies

Contact us: 415.949.5050

Month: June 2021

XPhyto Therapeutics Corp.’s (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Mescaline Program for Psychedelic Therapies is on Track

Researchers Find Link Between Cellular Aging, Epigenetic Changes in Cancer Patients

What Is Long COVID and What Do We Know About It?

Study Finds Mass Shooters May Be Suffering from Untreated Mental Illnesses

Improper Pain Management After Surgical Operations Linked to Opioid Epidemic

RYAH Group Inc. (CSE: RYAH) Cannabis Clinical Trials Improve Due to Dose-Measuring Devices

Vivos Therapeutics Inc. (NASDAQ: VVOS) Founder and Chief Medical Officer Shares Company’s Groundbreaking Work in New Book

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Discusses Its Vision for Addressing Patient Needs

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Targets Anxiety Disorders in Focus of Proprietary Psychedelic Treatments

Three Predictive Oncology Inc. (NASDAQ: POAI) Companies Participate in Popular Biotechnology Innovation Organization Digital Conference

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search